Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Oncology market: From $286B to $581B (2030)

<< Previous

Bullboard Posts

Next >>

Comment by BlueFrankyon May 08, 2023 5:00pm

318 Views

Post# 35437256

RE:RE:RE:RE:Oncology market: From $286B to $581B (2030)

Thanks Apophis and thank you as well Sciencefirst

I am optimistic that they are all paying close attention not only to our recent data but also the trajectory that we seem to be heading in with each new set of numbers and the possible chokehold on SOC

Here's hoping that one if not all of them are thinking of a preemptive strike, be it a JV or more.

Apophis I like your range, especially the upper end. I'm sure $20 would be satisfactory for some, I would hate to think that we're giving up anything short of a hundred for what we have and it's potential impact on indications too numerous to mention!

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”